Pharmala Biotech Holdings Inc

OTCPK:MDXXF (Canada)  
$ 0.06 -0.01625 (-21.78%) 09:42 AM EST
At Loss
P/B:
5.84
Volume:
1.30K
Avg Vol (2M):
26.75K
Trade In:
Volume:
1.30K
At Loss
Avg Vol (2M):
26.75K

Business Description

Description
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.16
Equity-to-Asset 0.54
Debt-to-Equity 0.19
Debt-to-EBITDA -1.22
Interest Coverage No Debt
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.85
Distress
Grey
Safe
Beneish M-Score 3.53
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 73.74
9-Day RSI 63.36
14-Day RSI 57.19
6-1 Month Momentum % -49.74
12-1 Month Momentum % -60.14

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.6
Quick Ratio 0.59
Cash Ratio 0.04
Days Inventory 93.91
Days Sales Outstanding 35.12

Dividend & Buy Back

Name Current Vs Industry Vs History

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 71.12
Operating Margin % -20.84
Net Margin % -47.31
FCF Margin % -71.76
ROE % -41.29
ROA % -25.36
ROIC % -13.47
ROC (Joel Greenblatt) % -12136.36
ROCE % -18.19

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 5.32
PB Ratio 5.84
EV-to-EBIT -33.34
EV-to-EBITDA -42.74
EV-to-Revenue 7.08
EV-to-FCF -7.84
Earnings Yield (Greenblatt) % -3
FCF Yield % -12.91